Three Takeda diabetes products get CHMP green light
This article was originally published in Scrip
Executive Summary
The European approval gate has been opened for three of Takeda's new type 2 diabetes therapies, which have today received positive opinions from the EMA's Committee for Medicinal Products for Human Use (CHMP).